stockrow
Friday 6 November 2026
Export INBS’s income statement to Excel — free account
Intelligent Bio Solutions Inc.
INBS Healthcare Medical Devices
Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025.
- Revenue
- +51.1%
- EPS
- +64.6%
- Free cash flow
- −31.6%
Quarter to June 2026, against a year earlier
1.99
0.23
+13.07%
Follow INBS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 2 | 0 | 2 | 3 | 3 | 4 | +67.8% | 6 | 9 | 12 | +43.1% | |
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | 53.36 | 45.81 | 40.85 | 48.63 | (51.4) pt | ||||||
| EBT | 0 | (5) | (7) | (3) | (7) | (8) | (11) | (10) | (11) | (12) | +50.7% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | (1,692.10) | (356.49) | (1,906.66) | (534.70) | (327.49) | (347.42) | (295.80) | (295.8) pt | ||||||
| Net income | 0 | (5) | (7) | (3) | (7) | (8) | (11) | (10) | (11) | (12) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 53.91 | 460.58 | 71.66 | 237.44 | 19.53 | 5.79 | 2.86 | n/m | |||||
| Earnings | (0.03) | (0.42) | (12.15) | (900.84) | (1,632.65) | (1,368.55) | (1,270.11) | (63.80) | (20.00) | (8.44) | +87.1% | ||||||
| Cash flow | (0.02) | (0.45) | (9.23) | (142.46) | (2,627.09) | (550.49) | (878.26) | (60.09) | (18.35) | (8.10) | +94.6% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (62.33) | (60.13) | (1.39) | (0.44) | (0.06) | n/m | ||||||
| Free cash flow | (0.02) | (0.45) | (9.23) | (142.46) | (2,627.09) | (612.82) | (938.39) | (61.48) | (18.79) | (8.16) | +94.8% | ||||||
| Book value | (0.49) | (0.36) | (7.64) | (1,489.94) | 3,489.91 | 1,073.08 | 438.93 | 51.37 | 5.34 | 3.59 | n/m | ||||||
| Shares, m | 12 | 12 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | (20.8%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 20.53 | 4.36 | 1.22 | 0.94 | 2.97 | 0.80 | 4.4 | ||||||
| P/B | — | — | — | 0.00 | 2.71 | 1.48 | 0.76 | 0.36 | 3.22 | 0.64 | 1.3 | ||||||
| EV/Sales | — | — | — | 0.00 | 15.24 | 1.93 | 1.74 | (0.24) | 3.43 | 0.43 | 3.2 | ||||||
| EV/FCF | — | — | — | (29.98) | (2.67) | (1.28) | (0.51) | 0.08 | (1.04) | (0.15) | (5.1) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | 0 | (5) | (6) | 0 | (11) | (3) | (7) | (10) | (10) | (12) | +54.1% | |||||
| Capex | — | — | — | — | — | 0 | (1) | 0 | 0 | 0 | (31.1%) | ||||||
| Free cash flow | 0 | (5) | (6) | 0 | (11) | (4) | (8) | (10) | (10) | (12) | +54.2% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | (7) | (5) | (6) | (5) | 15 | 6 | (2) | 3 | (1) | 2 | n/m | |||||
| Net debt | 6 | 4 | 5 | 5 | (10) | (5) | 1 | (4) | (1) | (4) | n/m | ||||||
| Shareholders’ equity | (6) | (4) | (5) | (5) | 15 | 7 | 4 | 8 | 3 | 5 | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | 0.00 | (402.29) | (304.18) | (131.73) | (57.84) | (48.56) | (93.64) | (84.17) | (95.95) | (123.13) | (123.1) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (76.87) | (455.43) | (160.96) | (147.21) | (372.07) | (606.86) | (606.9) pt | ||||||
| ROE | 0.00 | 52.84 | 44.82 | 25.43 | (144.28) | (77.12) | (207.80) | (171.13) | (192.21) | (306.76) | (306.8) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | 9 | 12 | 17 | 13 | 14 | 15 | +10.8% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.22 | 0.04 | 0.12 | 0.24 | 0.22 | 0.28 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Intelligent Bio Solutions Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NMTC NeuroOne Medical Technologies Corporation | $7.8M | — (loss-making) | — (loss-making) | +16.33% (above 0%: growing) | n/m | +26.91% (above 0%: growing) | 59.94% | (122.87%) | Compare |
| BMRA Biomerica, Inc. | $7.4M | — (loss-making) | 11.4× | −8.33% (below 0%: shrinking) | n/m | −199.25% (below 0%: shrinking) | 8.14% | (97.00%) | Compare |
| INBS Intelligent Bio Solutions Inc. | $5.8M | — (loss-making) | — (loss-making) | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −71.85% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | Compare |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| BDMD Baird Medical Investment Holdings Limited | $5.0M | — (loss-making) | — | — | n/m | −598.12% (below 0%: shrinking) | — | — | Compare |
| NVNO enVVeno Medical Corporation | $4.8M | — (loss-making) | — (loss-making) | +0.32% (above 0%: growing) | n/m | +27.64% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TNON Tenon Medical, Inc. | $4.4M | — (loss-making) | — (loss-making) | +126.77% (above 0%: growing) | n/m | −21.78% (below 0%: shrinking) | 63.64% | (262.24%) | Compare |
| WOK WORK Medical Technology Group LTD | $4.1M | — | — | — | — | −948.94% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $5.2M | — | — | −0.82% | — | −19.87% | 61.79% | (192.55%) |
Pay and ownership Proxy statement filed 19 September 2025
Ownership
Directors and executive officers, together
1.27%
Alyeska Master Fund, LP
9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement